NCT04319757 2024-12-05ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid TumorsAcepodia Biotech, Inc.Phase 1 Completed12 enrolled
NCT05395052 2023-09-21FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid TumorsFate TherapeuticsPhase 1 Terminated5 enrolled
NCT03841110 2023-05-01FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsFate TherapeuticsPhase 1 Completed37 enrolled